Skip Navigation LinksHome > June 2014 - Volume 41 - Issue 6 > Cost-Effectiveness Analysis of Annual Trichomonas vaginalis...
Sexually Transmitted Diseases:
doi: 10.1097/OLQ.0000000000000008
Original Study

Cost-Effectiveness Analysis of Annual Trichomonas vaginalis Screening and Treatment in HIV-Positive Women to Prevent HIV Transmission

Lazenby, Gweneth Bratton MD, MSCR*; Unal, Elizabeth Ramsey MD, MSCR; Andrews, Annie Lintzenich MD, MSCR; Simpson, Kit DrPH§

Collapse Box

Abstract

Background

Because of a high incidence of Trichomonas infection among HIV-positive women, annual screening and treatment are recommended. Trichomonas infection is associated with a 2-fold risk of HIV transmission. The objective of this study was to determine if annual screening is cost-effective for the prevention of new HIV cases in susceptible male partners secondary to Trichomonas infection in HIV-positive women.

Methods

A decision tree analysis was constructed to model the costs of Trichomonas screening, treatment, and follow-up. 200 women cycled through the model for a period of 12 months. One hundred women were unscreened and 100 were screened and treated per recommendations.

Results

Annual Trichomonas screening and treatment saves US$553 (US$475– US$645) per woman in the prevention of HIV transmission to male partners. The cost-effectiveness of this strategy was maintained across all assumptions in a sensitivity analysis.

Conclusions

Trichomonas screening and treatment for the purpose of decreasing new HIV infections is not only cost-effective but also cost saving in HIV-positive women. If Centers for Disease Control and Prevention treatment guidelines were followed in all HIV-positive women living in the United States, the lifetime cost of new HIV infections prevented would approximate US$159,264,000 and could potentially prevent new HIV cases secondary to female-to-male transmissions.

Copyright © 2014 American Sexually Transmitted Diseases Association All rights reserved.

Login